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Secretoneurin is a newly discovered 33-amino-acid peptide derived from secretogranin II (chromogranin C) that is found in sensory afferent C-fibers. 
We show here that secretoneurin triggers the selective migration of human monocytes in vitro and in vivo. Combinations of secretoneurin with 
the sensory neuropeptides, substance P or somatostatin, synergistically stimulate such migration. The attraction of monocytes represents he first 
established function of secretoneurin asa sensory neuropeptide. 
Secretoneurin; Secretogranin II; Neurogenic inflammation; Chemotaxis; Monocyte 
1. INTRODUCTION 
Secretoneurin, a newly discovered 33-amino-acid 
peptide derived from secretogranin II (chromogranin 
C), is widely distributed in the central and peripheral 
nervous and neuroendocrine systems [1,2]. In sensory 
C-fibers secretoneurin is co-localized with neuropep- 
tides [3] and released from these nerves by capsaicin 
(manuscript submitted). This localization suggests a 
possible role of this peptide in neurogenic inflamma- 
tion. An important step in the inflammatory response 
to capsaicin is the local accumulation of leukocytes [4]. 
Here we report that secretoneurin triggers the selective 
migration of human monocytes in vitro and in vivo. 
Combinations of secretoneurin with the sensory neu- 
ropeptides ubstance P or somatostatin synergistically 
stimulate such migration. 
2. MATERIALS AND METHODS 
Human mononuclear nd polymorphonuclear cells were isolated 
from heparinized forearm venous blood of healthy volunteers and 
resuspended in RPMI 1640 medium containing 0.5% BSA [5]. Chemo- 
taxis into nitrocellulose micropore filters to test attractants was meas- 
ured as described [5], using a modified 48-well Boyden chamber (Neu- 
roprobe, Bethesda, MD, USA). A 5-,urn pore nitrocellulose filter sep- 
arates the upper and lower chamber to allow only the actively migrat- 
ing monocytes or neutrophils to get through the pores. After 90 min 
and 40 min of incubation at 37°C for monocytes and neutrophils, 
respectively, the distance of migration of the leading front of cells was 
measured [6]. In some of the experiments, combinations oftest attrac- 
tants were added to the lower wells of the chambers. Cells were put 
in the upper compartments. Lyophilized substance P and somatostatin 
1-14 (Sigma, St. Louis, MO, USA) were reconstituted to stock solu- 
tions of 1 mM in acetic acid (0.2 N) and diluted into assay medium. 
*Corresponding author. Fax: (43) (512) 507 2419. 
Peptides derived from the primary amino acid sequence of secreto- 
granin II were synthesized by standard t-BOC chemistry and purified 
by reversed-phase high-performance liquid chromatography (HPLC). 
In some of the experiments, prior to use, secretoneurin was addition- 
ally purified by HPLC gel-filtration chromatography [1]. 
For measuring skin window migration of human monocytes, a 
rotating dental stone was used to cause superficial skin abrasions (10 
mm in diameter) [7]. An 8-/tm pore-sized nitrocellulose membrane 
(Sartorius Ltd., Grttingen, Germany) was moistened with medium 
(Hank's balanced salt solution containing 5% human serum albumin), 
placed over the abrasion and covered with an occlusive dressing. A
swab moistened with albumin-containing medium, secretoneurin or
Rantes (kindly provided by A.M. Krensky, Stanford Univ. Med. 
School, Stanford, CA, USA) was placed over the filter. Membranes 
were changed as described [7] and response rates obtained in serial 
determinations per field. Cells accumulated in the nitrocellulose mem- 
brane were fixed with 37% formaldehyde and stained for monocytes 
with non-specific esterase activity [8]. The distance of migration to- 
wards test attractants and that of medium alone was measured micro- 
scopically after 35 min of exposure on forearm lesions of three healthy 
volunteers. Mean migration ofmonocytes in the absence of attractants 
was about 65/tm. The difference between the distance of migration 
towards test attractants and that of buffer alone is shown. Statistics 
were calculated with the Mann-Whitney U-test. 
3. RESULTS AND DISCUSSION 
To test the effect of secretoneurin on the migration 
of human blood monocytes and neutrophils we per- 
formed a series of Boyden chamber assays on these 
cells. Fig. 1 demonstrates that secretoneurin is a potent 
attractor of blood monocytes. At a concentration of 100 
nM secretoneurin was as effective in attracting mon- 
ocytes as the positive control N-formylmethionine- 
leucyl-phenylalanine (fMet-Leu-Phe) at 10 and 100 nM 
(Fig. lb). Similar dose-response curves for monocyte 
migration were observed for rat and human secre- 
toneurin. Human neutrophils were attracted by secre- 
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toneurin to a small extent and only at high concentra- 
tions (1 ¢tM), whereas the positive control fMet-Leu- 
Phe (10 nM) was highly effective on these cells (Fig. la). 
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Fig.1. (a) Peripheral blood monocyte and neutrophil migration in 
response to secretoneurin i  vitro. Dose-response curves are shown 
at log M dilutions. The results are expressed as mean _+ S.E.M. of the 
difference between the distance of migration toward test attractant 
and that of buffer alone. The mean migration distance of the leading 
front of cells towards the buffer controls was around 60/ lm for 
monocytes (n -- 7) and 50 ,um for neutrophils (n -- 8). An identical 
experiment using fMet-Leu-Phe is given in the insert. (b) Peripheral 
blood monocyte migration in response to 10 nM of fMet-Leu-Phe, and 
100 nM of human [14] secretogranin II 152-184 (human secretoneurin, 
hSN, n -- 4), rat [15] secretogranin II 154-186 (rat secretoneurin, rSN, 
n = 7), C-terminal fragment of human secretoneurin (15 amino acids 
long, n = 4), human secretogranin II 1 16 (hAR-16, n -- 3), rat secre- 
togranin II 568 589 (YM-22, n = 3) and bovine [16] secretogranin II 
270 286 (EL-17, n = 3). 
Thus, secretoneurin acts preferentially on blood mon- 
ocytes. 
Stimulation of human monocyte migration was in- 
duced by both human and rat secretoneurin aswell as 
by a fragment of human secretoneurin consisting of its 
15 C-terminal amino acids (Fig. lb). Proteolytic leav- 
age of secretoneurin by trypsin (350/./g secretoneurin i  
80 ~tl of 0.1 M Tris-HC1, pH 7.9, containing 10 ¢tg 
trypsin for 3 h at 37°C) completely abolished its che- 
moattractant activity. As a further control, the effect of 
a specific antiserum was tested on migration induction 
by secretoneurin. Secretoneurin-induced attraction at 
optimal concentration (100 nM, rat) was significantly 
reduced from 12.5 + 1.4 ¢zm of migration distance to 
1.5 _+ 2.2tim (mean + S.E.M., n = 4; P = 0.028, Mann- 
Whitney U-test) by an immunoglobulin fraction iso- 
lated from the antiserum [1]. Migration of monocytes 
to fMet-Leu-Phe was unaffected by the antibody. Other 
peptides derived from the precursor secretogranin II, 
i.e. EL-17, the N-terminus (AR-16) and the C-terminus 
(YM-22) did not exhibit monocyte chemoattractant ac-
tivity (Fig. lb). Thus, chemoattraction is mediated only 
by secretoneurin and not by any other peptide derived 
from the precursor secretogranin II. Furthermore, the 
C-terminal 15 amino acids of secretoneurin are suffi- 
cient to promote this activity. 
In order to establish whether secretoneurin duces 
migration of monocytes by acting as a chemokinetic or 
chemotactic agent, a Zigmond-Hirsch checkerboard 
analysis was performed (Table I). Secretoneurin po- 
tently elicited migration of monocytes when present in 
excess in the lower compartment of the chemotaxis 
chambers. Addition of secretoneurin to the cells in the 
upper compartment did not augment migration. These 
results are consistent with a chemotactic action [5]. 
Secretoneurin is co-localized and released with other 
sensory neuropeptides in C-fiber nerves (see above). To 
investigate possible interactions of secretoneurin with 
Table I 
Effect of various concentration gradients of secretoneurin o  human 
peripheral blood monocyte migration into nitrocellulose micropore 
filters in vitro 
Migration (tim, mean + S.E.M., n = 3) 
Secretoneurin (M), upper chamber 
0 10 -u 10 -9 10 -7 
Secretoneurin 0 0 6 _+ 2.0 5 + 2.5 -1 + 3.0 
(M), lower 10 " 9 + 1.1 3 + 0.3 5 _+ 4.0 2 + 0.9 
chamber 10 -9 16+2.9 11 +1.7 3+1.6  -1+3.2  
10 7 27_+8.6 19+2.3 17+5.1 0_+4.2 
Each value represents he mean + S.E.M. of the difference between the 
distance of migration towards test attractants and that of buffer alone 
after 90 min of incubation at 37°C. Different concentrations of secre- 
toneurin were added to the upper and/or lower compartment of 
chemotaxis chambers. 
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other neuropeptides we tested monocyte chemotaxis by 
secretoneurin combination with substance P and so- 
matostatin, both of which have also been shown to 
attract human monocytes [5,9]. A combination of opti- 
mal concentrations of substance P or somatostatin with 
secretoneurin, deactivated the migratory response of 
monocytes (Fig. 2). This is typical for combinations of 
high doses of chemoattractants [10]. The mechanism of 
deactivation of monocyte chemotaxis induced by either 
a high dose of secretoneurin or by a combination with 
substance P or somatostatin is not fully understood. 
For other chemoattractants the same phenomenon was 
observed and explained with heterologous and homolo- 
gous desensitization of the receptor or a regulation at 
a postreceptorial level in the transduction sequence 
[10,11]. On the other hand, a combination of secre- 
toneurin with substance P or somatostatin atconcentra- 
tions which failed to induce significant migration of 
monocytes themselves, acted synergistically on mon- 
ocyte migration (Fig. 2). Chemoattractants at concen- 
trations that are either ineffective or produce a minor 
response are known to positively regulate a variety of 
leukocyte responses to physiologic or pharmacologic 
stimuli, termed priming [l 0]. The observed synergism in 
monocyte chemotaxis between low doses of sece- 
toneurin and other neuropeptides suggests that secre- 
toneurin also may exert a priming action on the human 
monocyte response. 
A possible interaction of secretoneurin with sub- 
stance P receptors was tested by the following experi- 
ment: at an optimal concentration of 10 nM, substance 
P attracted monocytes with a potency similar to that of 
100 nM of secretoneurin (13.3 + 1.7/lm and 13.2 + 1.6 
/~m, respectively; mean + S.E.M., n = 5). In the pres- 
ence of excess concentration of neurokinin-1 receptor 
antagonist [D-Pro9-(spiro-y-lactam)-Leu~°+Trp ~ 1]-Physa- 
laemin 1 11 (Peninsula, Belmont, CA, USA; 1 /,tM) 
monocyte migration to substance P (10 nM) was almost 
totally abolished (0.7 + 3.0/lm; n = 3; P = 0.046). On 
the other hand, the response to secretoneurin was not 
affected (13.8 + 1.9/1m, n = 5). The neurokinin-2 recep- 
tor antagonist [Tyr 5, D-Trp 6's'9, Arg~°]-Neurokinin A 4- 
10 (Peninsula, Belmont, CA, USA; 1/IM) inhibited nei- 
ther substance P- nor secretoneurin-induced hemotaxis 
(10.3 + 0.3/ lm and 22.8 + 2.1/~m, respectively; n = 3). 
Thus the ability of secretoneurin to induce monocyte 
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Fig. 2. Peripheral blood monocyte migration in response to combinations of secretoneurin (SN) with somatostatin (SOM) and substance P (SP) 
respectively, atoptimal and suboptimal concentrations (log M). Combination of the peptides at suboptimal concentrations synergistically stimulated 
migration (a, SN vs. SN plus SOM, and SOM vs. SN plus SOM, P < 0.05, n = 5; b, SN vs. SN plus SP, and SP vs. SN plus SP, P < 0.05, n = 6). 
Combination at optimal concentrations significantly reduced the chemoattractant effect of the peptides (a, SN vs. SN plus SOM, and SOM vs. 
SN plus SOM, P < 0.01, n = 5; b, SN vs. SN plus SP, P < 0.005, SP vs. SN plus SIC', P < 0.01, n = 6). 
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Table II 
Skin window migration of human monocytes 
Monocyte migration into a 
skin window (//m) 
n Mean + S.E.M. P value 
Rat secretoneurin, 10 -7 M 9 11.1 1.98 0.046 
Human secretoneurin, 10 -7 M 4 12.5 3.18 0.021 
Human secretogranin II 
1-16, 10 7 M 3 -2.3 2.33 0.827 
Rantes,  10 -7 M 3 8.7 1.86 0.049 
Our  studies show that secretoneurin, a novel sensory 
neuropeptide, found in afferent C-fibers attracts b lood 
monocytes in a concentrat ion-dependent manner. Ap-  
pl ication of  secretoneurin in vivo to skin lesions en- 
hances monocyte locomot ion towards the accumulat ion 
at the site of  injury. These results suggest that secre- 
toneurin, released from afferent fibers, may part ic ipate 
in neurogenic inf lammation and immune system regula- 
tion. Secretoneurin can therefore be added to the group 
of  neuropept ides biological ly active in the sensory sys- 
tem. 
The effect of rat and human secretoneurin o the rate of accumulation 
and locomotion of human monocytes inresponse to injury in vivo was 
investigated. Statistics were calculated with the Mann Whitney 
U-test. 
attract ion does not appear to involve neurokinin-1 or 
neurokinin-2 receptors. 
A human skin window technique using micropore 
membranes was employed in order to test the effect of  
secretoneurin on a rapid inf lammatory response leading 
to cellular infi ltration of  insulted tissue in vivo [7]. The 
distance of  migrat ion of  the leading front of  monocytes 
into the filter was measured as a quantitat ive stimate 
of  the rate of  accumulat ion and locomotion in response 
to injury. Table II shows that secretoneurin significantly 
augmented the migrat ion distance of  monocytes in vivo. 
Rantes, a selective monocyte-attract ing chemokine [12] 
similarly affected the migrat ion distance of  monocytes,  
whereas a low concentrat ion of  RANTES (1 nM) or the 
human secretogranin II 1 16 (AR-16) peptide, which 
did not  induce monocyte migrat ion in vitro (Fig. l b), 
also failed to st imulate monocyte accumulat ion in vivo. 
Superoxide anion release from adherent mononu-  
clear leukocytes, measured by reduction of  ferricyto- 
chrome-c [13] could not be induced by 100 nM of  secre- 
toneurin after pretreatment of cells for 24 h with either 
10% fetal calf serum or with 1000 U/ml of  interferon-y 
(not shown). Pretreatment of  adherent mononuclear  
leukocytes with 1000 U/ml of  interferon-?" significantly 
activated phorbol  12-myristate 13-acetate (100 ng/ml)- 
tr iggered respirat ion burst activity, whereas 100 nM of  
secretoneurin failed to prime this effect. Moreover,  ad- 
dit ion of  100 nM of  secretoneurin to 1000 U/ml of  
interferon-), did not alter interferon-7" induced pr iming 
(not shown). 
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